ArticleGenome medicine2011
Classification of unknown primary tumors with a data-driven method based on a large microarray reference database.
Article in Genome medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.Briefings in bioinformatics · 2024Pooled it
- Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy.Advances in cancer research · 2021Pooled it
- Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis.Frontiers in oncology · 2023Article
- Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care.Oncotarget · 2017Article
- Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.Journal of the National Cancer Institute · 2016Article
- Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
- A novel atlas of gene expression in human skeletal muscle reveals molecular changes associated with aging.Skeletal muscle · 2015Article
- RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin.Neoplasia (New York, N.Y.) · 2014Article
- Reuse of public genome-wide gene expression data.Nature reviews. Genetics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a new method to analyze cancer of unknown primary origin (CUP) samples. Our method achieves good results with classification accuracy (88% leave-one-out cross validation for primary tumors from 56 categories, 78% for CUP samples), and can also be used to study CUP samples on a gene-by-gene basis. It is not tied to any a priori defined gene set as many previous methods, and is adaptable to emerging new information.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.